VBIO•Valion Bio expects top-line results in early December 2026 from a government-funded animal study testing whether a single dose of Entolimod given 24 hours after radiation exposure improves survival.
Valion Bio expects top-line results in early December 2026 from a government-funded animal study of Entolimod for gastrointestinal acute radiation syndrome. The study evaluates whether a single dose given 24 hours after radiation exposure improves survival; the National Institute of Allergy and Infectious Diseases is funding it, and preclinical safety findings were positive.
